Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [Ets1 scRNAseq]

ABSTRACT: Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [Ets1 scRNAseq]

PROVIDER: PRJNA903380 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22348076.fastq.gz	Fastqsanger.gz
	SRR22348077.fastq.gz	Fastqsanger.gz
	SRR22348078.fastq.gz	Fastqsanger.gz
	SRR22348079.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [Ets1 ATAC-Seq]

Project description:Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [Ets1 ATAC-Seq]

| PRJNA1000988 | ENA

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [Ets1 scRNAseq]

Project description:The gene regulatory network (GRN) underlying CTL differentiation and whether Tex responses can be functionally reinvigorated are incompletely understood. Here, we systematically mapped causal GRNs via single-cell CRISPR (scCRISPR) screens in vivo and discovered checkpoints for CTL differentiation.

2023-11-15 | GSE218372 | GEO

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [Ets1 ATAC-Seq]

2023-11-15 | GSE239801 | GEO

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer

Project description:Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer

| PRJNA895421 | ENA

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [Rbpj_scRNAseq]

Project description:Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [Rbpj_scRNAseq]

| PRJNA895425 | ENA

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [microarray]

Project description:Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [microarray]

| PRJNA895088 | ENA

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [scCRISPR]

Project description:Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [scCRISPR]

| PRJNA896168 | ENA

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [Ikzf1_scRNAseq]

Project description:Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [Ikzf1_scRNAseq]

| PRJNA895422 | ENA

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer.

Project description:CD8+ cytotoxic T cells (CTLs) orchestrate antitumour immunity and exhibit inherent heterogeneity1,2, with precursor exhausted T (Tpex) cells but not terminally exhausted T (Tex) cells capable of responding to existing immunotherapies3-7. The gene regulatory network that underlies CTL differentiation and whether Tex cell responses can be functionally reinvigorated are incompletely understood. Here we systematically mapped causal gene regulatory networks using single-cell CRISPR screens in vivo and discovered checkpoints for CTL differentiation. First, the exit from quiescence of Tpex cells initiated successive differentiation into intermediate Tex cells. This process is differentially regulated by IKAROS and ETS1, the deficiencies of which dampened and increased mTORC1-associated metabolic activities, respectively. IKAROS-deficient cells accumulated as a metabolically quiescent Tpex cell population with limited differentiation potential following immune checkpoint blockade (ICB). Conversely, targeting ETS1 improved antitumour immunity and ICB efficacy by boosting differentiation of Tpex to intermediate Tex cells and metabolic rewiring. Mechanistically, TCF-1 and BATF are the targets for IKAROS and ETS1, respectively. Second, the RBPJ-IRF1 axis promoted differentiation of intermediate Tex to terminal Tex cells. Accordingly, targeting RBPJ enhanced functional and epigenetic reprogramming of Tex cells towards the proliferative state and improved therapeutic effects and ICB efficacy. Collectively, our study reveals that promoting the exit from quiescence of Tpex cells and enriching the proliferative Tex cell state act as key modalities for antitumour effects and provides a systemic framework to integrate cell fate regulomes and reprogrammable functional determinants for cancer immunity.

| S-EPMC10700132 | biostudies-literature

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [Rbpj_ATAC-seq]

Project description:Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [Rbpj_ATAC-seq]

| PRJNA895423 | ENA